Generic Pharmaceuticals Contract Manufacturing Market Size- By Drug Type, By Product, By Route of Administration, By Application- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Description

Global Generic Pharmaceuticals Contract Manufacturing Market Overview:

According to SPER Market Research, the Global Generic Pharmaceuticals Contract Manufacturing Market is estimated to reach USD 121.42 billion by 2032 with a CAGR of 6.04%.

The industry's growth is being driven by the advantages of outsourcing in terms of cost and time savings. A generic medication is a prescription medication that shares the same chemical components as a medication that was first covered by a chemical patent. Following the expiration of the patents on the original medications, generic medications may be sold. Generics function as well in terms of the medical profile because the active chemical component is the same. The active pharmaceutical ingredient (API) in a generic medication is the same as that in the brand-name medication, but there may be differences in the manufacturing method, formulation, excipients, colour, taste, and packaging. Around the world, a sizable population is afflicted with chronic illnesses. For instance, according to the CDC, 6 out of 10 persons in the U.S. have at least one chronic condition, and 4 out of 10 have two or more. Long-term treatment is necessary for chronic diseases. The demand for cost-effective generic drugs for the treatment of chronic diseases is rising as a result of the high cost of pharmaceuticals. It is anticipated that the presence of numerous important firms in this area will have a substantial impact on its development.

Impact of COVID-19 on the Global Generic Pharmaceuticals Contract Manufacturing Market:

This is anticipated to boost the industry's expansion following the pandemic. The regulatory approval process for generic medications has improved. Advancements in this sector are anticipated to benefit the production of generic medications and, as a result, assist the expansion of the sector. The Japanese government is continually working to develop the nation's market for generic medications. The government is also urging medical institutions to promote the use of generic medications and is taking steps to increase the availability of generics in the nation. In the upcoming years, this is anticipated to enhance CMO operations for generic drugs. The amount spent globally on medications is also increasing. The region's growth is further supported by the increasing tendency of pharmaceutical businesses in the area to outsource non-core activities like manufacturing.

Scope of the Report:

Market size available for years: 2019-2032

Base year considered: 2021

Forecast period: 2022-2032

Segments covered: By Drug Type, By Product, By Route of Administration, By Application

Regions covered: Asia Pacific, Europe, Middle East and Africa,North America, Latin America

Companies Covered: Acme Generics Pvt Ltd., Alcami Corp. Inc., Aurobindo Pharma, Cambrex Corp., Catalent, Inc, Curia Global, Inc., Jubilant Generics Ltd., Metric Contract Services, Pfizer CentreOne, Recipharm Ab, Siegfried Holding AG, Syngene International Limited

Global Generic Pharmaceuticals Contract Manufacturing Market Segmentation:

By Drug Type: Based on the Drug Type, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Branded, Unbranded.

By Product: Based on the Product, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; API, Drug Product.

By Route of Administration: Based on the Route of Administration, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Oral, Parenteral, Topical, Others.

By Application: Based on the Application, Global Generic Pharmaceuticals Contract Manufacturing Market is segmented as; Anticoagulants, Antidiabetic, Cardiovascular, HIV antivirals, Immunology, Neurology, Oncology, Pain, Respiratory, Others.

By Region: The lowest CAGR is anticipated in Asia Pacific over the projected period, mostly as a result of the region's inexpensive manufacturing of generic medications.

Product Code: PHAR2215

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Generic Pharmaceuticals Contract Manufacturing Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4.Heat map analysis

6. Competitive Landscape

6.1. Global Generic Pharmaceuticals Contract Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Generic Pharmaceuticals Contract Manufacturing

7. Global Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type, 2019-2032 (USD Million)

7.1. Branded
7.2. Unbranded

8. Global Generic Pharmaceuticals Contract Manufacturing Market, By Product, 2019-2032 (USD Million)

8.1. API
8.2. Drug Product

9. Global Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration, 2019-2032 (USD Million)

9.1. Oral
9.2. Parenteral
9.3. Topical
9.4. Others

10. Global Generic Pharmaceuticals Contract Manufacturing Market, By Application, 2019-2032 (USD Million)

10.1. Anticoagulants
10.2. Antidiabetic
10.3. Cardiovascular
10.4. HIV antivirals
10.5. Immunology
10.6. Neurology
10.7. Oncology
10.8. Pain
10.9. Respiratory
10.10. Others

11. Global Generic Pharmaceuticals Contract Manufacturing Market, By Region, 2019-2032 (USD Million)

11.1. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2019-2025)
11.2. Global Generic Pharmaceuticals Contract Manufacturing Size and Market Share by Region (2026-2032)
11.3. Asia-Pacific
- 11.3.1. Australia
- 11.3.2. China
- 11.3.3. India
- 11.3.4. Japan
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
11.4 Europe
- 11.4.1 France
- 11.4.2 Germany
- 11.4.3 Italy
- 11.4.4 Spain
- 11.4.5 United Kingdom
- 11.4.6 Rest of Europe
11.5 Middle East & Africa
- 11.5.1 Kingdom of Saudi Arabia
- 11.5.2 United Arab Emirates
- 11.5.3 Rest of Middle East & Africa
11.6 North America
- 11.6.1 Canada
- 11.6.2 Mexico
- 11.6.3 United States
11.7 Latin America
- 11.7.1 Argentina
- 11.7.2 Brazil
- 11.7.3 Rest of Latin America

12. Company Profiles

12.1 Acme Generics Pvt Ltd.
- 12.1.1 Company details
- 12.1.2 Financial outlook
- 12.1.3 Product summary
- 12.1.4 Recent developments
12.2 Alcami Corp. Inc.
- 12.2.1 Company details
- 12.2.2 Financial outlook
- 12.2.3 Product summary
- 12.2.4 Recent developments
12.3 Aurobindo Pharma
- 12.3.1 Company details
- 12.3.2 Financial outlook
- 12.3.3 Product summary
- 12.3.4 Recent developments
12.4 Cambrex Corp.
- 12.4.1 Company details
- 12.4.2 Financial outlook
- 12.4.3 Product summary
- 12.4.4 Recent developments
12.5 Catalent, Inc
- 12.5.1 Company details
- 12.5.2 Financial outlook
- 12.5.3 Product summary
- 12.5.4 Recent developments
12.6 Curia Global, Inc.
- 12.6.1 Company details
- 12.6.2 Financial outlook
- 12.6.3 Product summary
- 12.6.4 Recent developments
12.7 Jubilant Generics Ltd.
- 12.7.1 Company details
- 12.7.2 Financial outlook
- 12.7.3 Product summary
- 12.7.4 Recent developments
12.8 Metric Contract Services
- 12.8.1 Company details
- 12.8.2 Financial outlook
- 12.8.3 Product summary
- 12.8.4 Recent developments
12.9 Pfizer CentreOne
- 12.9.1 Company details
- 12.9.2 Financial outlook
- 12.9.3 Product summary
- 12.9.4 Recent developments
12.10 Recipharm Ab
- 12.10.1 Company details
- 12.10.2 Financial outlook
- 12.10.3 Product summary
- 12.10.4 Recent developments
12.11 Siegfried Holding AG
- 12.11.1 Company details
- 12.11.2 Financial outlook
- 12.11.3 Product summary
- 12.11.4 Recent developments
12.12 Syngene International Limited
- 12.12.1 Company details
- 12.12.2 Financial outlook
- 12.12.3 Product summary
- 12.12.4 Recent developments